The latest price target for VYNE Therapeutics (NASDAQ:VYNE) was reported by BTIG on November 18, 2024. The analyst firm set a price target for $8.00 expecting VYNE to rise to within 12 months (a possible 175.86% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for VYNE Therapeutics (NASDAQ:VYNE) was provided by BTIG, and VYNE Therapeutics initiated their buy rating.

There is no last upgrade for VYNE Therapeutics

There is no last downgrade for VYNE Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VYNE Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VYNE Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest VYNE Therapeutics (VYNE) rating was a initiated with a price target of $0.00 to $8.00. The current price VYNE Therapeutics (VYNE) is trading at is $2.90, which is within the analyst’s predicted range.